XTX Topco Ltd Makes New $661,000 Investment in Amgen Inc. (NASDAQ:AMGN)

XTX Topco Ltd acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,115 shares of the medical research company’s stock, valued at approximately $661,000.

A number of other large investors also recently added to or reduced their stakes in the stock. Concorde Asset Management LLC raised its position in shares of Amgen by 4.8% in the second quarter. Concorde Asset Management LLC now owns 888 shares of the medical research company’s stock valued at $277,000 after buying an additional 41 shares during the last quarter. MRP Capital Investments LLC acquired a new stake in shares of Amgen in the second quarter valued at about $219,000. Marathon Trading Investment Management LLC acquired a new stake in shares of Amgen in the second quarter valued at about $469,000. Seven Eight Capital LP acquired a new stake in shares of Amgen in the second quarter valued at about $845,000. Finally, Lokken Investment Group LLC raised its position in shares of Amgen by 13.6% in the second quarter. Lokken Investment Group LLC now owns 3,742 shares of the medical research company’s stock valued at $1,169,000 after buying an additional 449 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 target price (up previously from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Bank of America increased their target price on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $380.00 target price on shares of Amgen in a research note on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $327.28.

Amgen Stock Performance

NASDAQ:AMGN opened at $335.61 on Tuesday. The firm’s fifty day moving average price is $329.68 and its 200 day moving average price is $306.47. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The firm has a market cap of $180.03 billion, a price-to-earnings ratio of 47.94, a price-to-earnings-growth ratio of 2.93 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter last year, the business earned $5.00 earnings per share. The business’s quarterly revenue was up 20.1% on a year-over-year basis. On average, sell-side analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were given a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.68%. Amgen’s payout ratio is currently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.